GENB
Generate Biomedicines, Inc.Company with tickers: GENB
CIK
2100782
CUSIP
370920100
Shares Outstanding
128,192,484
13F Activity (30d)
46 filings
46 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $7,224,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $71,336,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Research & Development | $57,812,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Operating Income | $-64,112,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Net Income | $-61,446,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Basic) | $-1.07 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Diluted) | $-1.07 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |